

file w/ #4

Sheet 01 of 02

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. PENN-0701	Serial No. 09/419,328
	Applicant ALAIN H. ROOK	
	Filing Date OCTOBER 15, 1999	Group 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


FH ↓	AA	Brunda, et al., "Antitumor and Antimetastatic Activity of Interleukin 12 against Murine Tumors", <i>J. Exp. Med.</i> 1993 178:869-879
	AB	Diamandidou, E., et al., "Mycosis Fungoides and Sezary Syndrome", <i>Blood</i> 1996 88:2385-2409
	AC	Haku, et al., "Interleukin-12-Mediated Killer Activity in Lung Cancer Patients", <i>Cytokine</i> 1997 9:846-852
	AD	Hiramatsu, K., et al., "Generation of killer activity by interleukin-12 of mononuclear cells in malignant pleural effusions due to lung cancer", <i>Cancer Immunol. Immunother.</i> 1998 46:1-6
	AE	Hsieh, C.S., et al., "Development of T _H 1 CD4 ⁺ T Cells Through IL-12 Produced by Listeria-Induced Macrophages", <i>Science</i> 1993 260:547-549
	AF	Nishimura, et al., "Systemic in vivo antitumor activity of interleukin-12 against both transplantable and primary tumor", <i>Immunol. Lett.</i> 1995 48:149-152
	AG	Rook, et al., "Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses", <i>Blood</i> 1999 94:902-908
	AH	Rook, et al., "The Immunopathogenesis of Cutaneous T-Cell Lymphoma", <i>Arch. Dermatol.</i> 1993 129:486
	AI	Rook, et al., "IL-12 Reverses Cytokine and Immune Abnormalities in Sezary Syndrome ¹ ", <i>J. Immunol.</i> 1995 154:1491-1498

EXAMINER

Fora Hamed

DATE CONSIDERED

9/27/00



Sheet 02 of 02

Form PTO-1449 Modified

Docket No.
PENN-0701Serial No.
09/419,328List of Patents and Publications
Cited by Applicant
(Use several sheets if necessary)Applicant
ALAIN H. ROOK

U.S. Department of Commerce

Filing Date
OCTOBER 15, 1999Group
1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

F#	AJ	Rook, et al., "The Potential Therapeutic Role of Interleukin-12 in Cutaneous T-Cell Lymphoma ^α ", <i>Ann. NY Acad. Sci.</i> 1996 795:310-318
	AK	Rook, et al., "Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis", <i>Clin. Ex. Immunol.</i> 1997 107:16-20
	AL	Sahin, et al., "Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors", <i>Cancer Immunol. Immunother.</i> 1996 42:9-14
	AM	Seo N., et al., "Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sezary syndrome: its enhancement by interferon-gamma (IFN-γ) and IL-12 and fluctuations in association with disease activity", <i>Clin. Exp. Immunol.</i> 1998 112:403-409
	AN	Verbik, et al., "In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma", <i>Clin. Exp. Metastasis</i> 1996 42:219-229
	AO	Vowels, et al., "Aberrant Cytokine Production by Sezary Syndrome Patients: Cytokine Secretion Pattern Resembles Murine Th2 Cells", <i>J. Invest. Dermatol.</i> 1992 99:90-94
	AP	Vowels, et al., "Th2 cytokine mRNA Expression in Skin in Cutaneous T-Cell Lymphoma", <i>J. Invest. Dermatol.</i> 1994 103:669-673
	AQ	Vowels, et al., "Normalization of Cytokine Secretion Patterns and Immune Function Following Disappearance of Malignant Clone from the Peripheral Blood of a Sezary Syndrome (SzS) Patient", <i>J. Invest. Dermatol.</i> 1993 100:556
EXAMINER	Bona H. Smith	
DATE CONSIDERED	9/27/00	